Compounds, formulations, and methods for treating or preventing rosacea

Details for Australian Patent Application No. 2004242967 (hide)

Owner Sansrosa Pharmaceutical Development, Inc.

Inventors Dejovin, Jack; Rossi, Thomas M.

Agent Griffith Hack

Pub. Number AU-B-2004242967

PCT Pub. Number WO2004/105703

Priority 60/473,611 27.05.03 US; 10/853,585 25.05.04 US

Filing date 26 May 2004

Wipo publication date 9 December 2004

Acceptance publication date 28 May 2009

International Classifications

A61K 31/00 (2006.01)

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/4164 (2006.01) - 1,3-Diazoles

A61K 31/498 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

19 January 2006 PCT application entered the National Phase

  PCT publication WO2004/105703 Priority application(s): WO2004/105703

28 May 2009 Application Accepted

  Published as AU-B-2004242967

24 September 2009 Standard Patent Sealed

22 April 2010 Assignment Registered

  Sansrosa Pharmaceutical Development, Inc. The patent has been assigned to Galderma Laboratories, Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004242976-Apparatus for dispersing volatile materials into the environment

2004242964-Soluble CLCA-1 and antagonists to CLCA-1